Examining the link between PSA levels and PET/CT imaging in prostate cancer
Correlation Between Prostate-Specific Antigen (PSA) Levels and Fluorine-18 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (F-18 PSMA PET/CT) Scan Findings in Patients With Prostate Cancer
This study is trying to see how PSA levels relate to PET/CT scan results in men with prostate cancer to improve their treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 59 (estimated) |
| Sex | Male |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Asyut) |
| Trial ID | NCT06209853 on ClinicalTrials.gov |
What this trial studies
This observational study aims to correlate prostate-specific antigen (PSA) levels with findings from F-18 PSMA PET/CT scans in patients diagnosed with prostate cancer. It will evaluate how these imaging results impact patient management decisions. The study focuses on male patients with confirmed prostate cancer who are referred for PET/CT imaging for various clinical indications. By analyzing the relationship between PSA levels and PET/CT results, the study seeks to enhance diagnostic accuracy and treatment strategies for prostate cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are male patients with pathologically confirmed prostate cancer who are scheduled for F-18 PSMA PET/CT imaging.
Not a fit: Patients with undifferentiated prostate cancer or those who are severely ill may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and treatment outcomes for prostate cancer patients by providing better diagnostic tools.
How similar studies have performed: Previous studies have shown promising results in correlating PSA levels with PET/CT imaging outcomes, indicating that this approach has been validated in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male Patients with pathologically proven prostate cancer who will be referred to nuclear medicine unit to perform F18 PSMA for different indications Exclusion Criteria: * Undifferentiated prostate cancer. * Studies with motion artifacts, or those in which patient can't stay stable or calm during acquisition. * Severely ill patients that hinder imaging.
Where this trial is running
Asyut
- Assiut university hospital — Asyut, Egypt (Recruiting)
Study contacts
- Principal investigator: Aalaa W Hussein, master — Assiut University
- Study coordinator: Aalaa W Hussein, master
- Email: aalaawhy@gmail.com
- Phone: +201092855007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.